APC and neoplasm: The T cell activation properties of the [CD80/OVA] NPs were also confirmed (Figure 14D).[65] In this study, CD80 and OVA were engineered to construct a biomimetic nanoscale APC platform, which directly presented tumor antigens to activate T cells for tumor therapy.